Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

Visualizza tutta la documentazione

59352-U21

Supelco

Discovery® C8 (5 µm) HPLC Columns

L × I.D. 5 cm × 2.1 mm, HPLC Column

Sinonimo/i:

C8 Reversed-Phase Chromatography Column

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Codice UNSPSC:
41115700
eCl@ss:
32110501
NACRES:
SB.52

Nome del prodotto

Discovery® C8 HPLC Column, 5 μm particle size, L × I.D. 5 cm × 2.1 mm

Materiali

stainless steel column

Livello qualitativo

100

agenzia

suitable for USP L7

Nome Commerciale

Discovery®

Caratteristiche

endcapped

Produttore/marchio commerciale

Discovery®

Confezionamento

1 ea of

Grado di funzionalizzazione

7.5% Carbon loading

Parametri

≤70 °C temp. range
400 bar pressure (5801 psi)

tecniche

HPLC: suitable
LC/MS: suitable

Lungh. × D.I.

5 cm × 2.1 mm

Area superficiale

200 m2/g

Copertura della superficie

3.4 μmol/m2

Impurezze

<10 ppm metals

Matrice

silica gel, high purity, spherical base material
fully porous particle

Gruppo funzionale matrice

C8 (octyl) phase

Dimensione particelle

5 μm

Dimensione pori

180 Å

Intervallo di pH d’impiego

2-8

applicazioni

food and beverages

Tecnica di separazione

reversed phase

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Categorie correlate

Applicazioni


  • UHPLC-MS/MS method for chiral separation of 3-hydroxy fatty acids: Highlighting the adaptability of the Discovery® C8 column, this paper details its application in a sophisticated chiral separation method, underscoring its importance in clinical diagnostics and research (Fu et al., 2023).

Caratteristiche e vantaggi

  • Excellent reproducibility
  • Faster separation of strongly hydrophobic analytes than C18 columns
  • Stable, low-bleed LC-MS separations
  • Exceptional peak shapes for basic and acidic compounds
  • Compatible with low organic/highly aqueous mobile phases

Note legali

Discovery is a registered trademark of Merck KGaA, Darmstadt, Germany

Prodotti correlati

N° Catalogo
Descrizione
Determinazione del prezzo

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number
281567-02
281567-01
281563-02
281563-01
279685-02

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Cerca un COA

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Scott C Bell et al.
Pharmacology & therapeutics, 145, 19-34 (2014-06-17)
With the discovery of the CFTR gene in 1989, the search for therapies to improve the basic defects of cystic fibrosis (CF) commenced. Pharmacological manipulation provides the opportunity to enhance CF transmembrane conductance regulator (CFTR) protein synthesis and/or function. CFTR
Bo-Rui Kang et al.
Bioorganic & medicinal chemistry letters, 25(24), 5808-5812 (2015-11-08)
2-Benzylisoquinolin-1(2H)-ones has been proposed as vasodilative agents on the basis of scaffold hopping. In the present study, a series of 2-benzylisoquinolin-1(2H)-ones were synthesized. Their vasodilative effects were evaluated by wire myograph on isolated rat mesenteric arterial ring induced contraction with
Hugo M Botelho et al.
Scientific reports, 5, 9038-9038 (2015-03-13)
Plasma membrane proteins are essential molecules in the cell which mediate interactions with the exterior milieu, thus representing key drug targets for present pharma. Not surprisingly, protein traffic disorders include a large range of diseases sharing the common mechanism of
M Q Zhang et al.
Die Pharmazie, 46(10), 687-700 (1991-10-01)
The rapid growth in the quinolone research changed the whole face of the previous SAR concepts. So far structural modifications at all positions of the quinolone nucleus except the 4-oxo group have successfully lead to the discovery of potent antimicrobial
G L Bundy et al.
The Journal of biological chemistry, 261(2), 747-751 (1986-01-15)
The gorgonian coral Pseudoplexaura porosa contains a lipoxygenase capable of converting exogenous arachidonic acid into (8R)-8-hydroperoxy-5,9,11,14-eicosatetraenoic acid. The (8R)- (or 8-L-) configuration in this product, opposite to that observed in previously reported 8-lipoxygenase products, was determined unambiguously by comparison of
Visualizza tutti i documenti correlati

Contenuto correlato

Discovery C18 and C8 HPLC Columns

Discovery C18 and C8 HPLC Columns products offered

Global Trade Item Number

SKUGTIN
59352-U214061833507643

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.